Polaris Market Research Releases AI in Genomics Market Outlook 2026-2034: Precision Medicine and AI-Powered Genomics Drive Industry Growth

New industry analysis projects a USD 21.08 billion AI in genomics market by 2034 as precision medicine adoption, genomic data expansion, and AI-enabled analytics platforms accelerate commercial opportunities across healthcare and life sciences.

Market Size 2025	Forecast 2034	CAGR 2026-2034	Leading Region
USD 1.04 Billion	USD 21.08 billion	39.79%	North America (43.0%)

Source: Polaris Market Research Analysis

Polaris Market Research & Consulting has released its AI in Genomics Market Report 2026-2034. The market was valued at USD 1.04 billion in 2025 and is projected to reach USD 21.08 billion by 2034, registering a CAGR of 39.79% during the forecast period. Growth in the market is attributable to the increasing adoption of precision medicine, genomic sequencing, and AI applications within the healthcare and life sciences industries. Increased investments in genomic data analysis tools, cloud-based bioinformatics solutions, and AI-driven drug discovery platforms is expected to continue to facilitate market growth.

Increasing business operations are observed as companies aim to enhance their ability for interpreting genomics and making clinical decisions. In October 2025, GeneDx stated that the U.S. Food and Drug Administration awarded the Breakthrough Device Designation for its ExomeDx and GenomeDx genomic test solutions after acquiring Fabric Genomics. The National Institutes of Health continues to expand its Bridge2AI initiative to develop AI-ready biomedical datasets and tools that improve data accessibility and interoperability across research environments. Growing deployment of accelerated computing platforms and cloud-native genomic analytics solutions is also increasing adoption across research institutes, hospitals, and biopharmaceutical companies.

“AI in genomics is moving beyond research-focused applications and becoming an important component of clinical and commercial decision-making. Organizations that combine high-quality genomic data, advanced analytics capabilities, and scalable infrastructure are expected to be well positioned to capture long-term growth opportunities across precision medicine and drug discovery.” — Prajakta Bengale, Senior Healthcare Analyst

AI in Genomics Market Investment Signals 2026

Investment Theme	Market Signal	Business Implication
Clinical Validation Race	GeneDx reported FDA Breakthrough Device Designation on 6 Oct 2025.	Screen AI-genomics assets for evidence, clinical utility, and regulatory readiness before paying software multiples.
Dataset Infrastructure Shift	NIH Bridge2AI is building flagship AI-ready biomedical datasets in 2026.	Prioritize platforms that can use multi-modal data without creating consent or provenance risk.
Compute Bottleneck Pricing	NVIDIA Clara supports accelerated genomics workflows accessed in 2026.	Model GPU, cloud, and pipeline costs as margin variables, not back-office infrastructure.
Clinical Workflow Formalization	SOPHiA GENETICS continued 2026 commercial platform updates.	Favor vendors embedded in hospital and lab workflows over point-tool analytics providers.

Source: Polaris Market Research Analysis

Three Market Developments Reshaping the AI in Genomics Industry in 2026

Precision Medicine Is Expanding Commercial Demand

Medical professionals are increasingly incorporating information from the genomics field into their work in order to make better personal treatment decisions. Increasing use of genomic interpretation software using AI technology helps to enhance diagnostics and patient outcomes. An increasing adoption of precision medicine initiatives is expected to present more business opportunities for platform and health IT companies.

AI-Ready Datasets Are Becoming Strategic Assets

Improvements in the availability of genomic and biomedical big data have been boosting the accuracy of AI algorithms as well as driving scientific research uses cases. Companies that are able to showcase efficient data management, interoperability, and analysis skills are likely to gain a competitive advantage. The need for genomic data platforms remains on the rise.

Advanced Computing Infrastructure Is Supporting Scale

Applications of artificial intelligence in genomics need substantial computing power in order to handle large and complex datasets. Adoption of accelerated computing technologies and cloud infrastructure is contributing to improvements in workflows and deployment of AI-driven genomics solutions. Infrastructure capability evaluation is becoming more common during the technology selection process.

Request a free sample copy or read the full market insights : AI in Genomics Market Report

About the Polaris AI in Genomics Market Report 2026-2034

The report analyzes market size, forecasted growth, technological trends, geographical market potential, competitive landscape, and investment opportunity in the global artificial intelligence in genomics industry. It is aimed at healthcare organizations, biotech firms, pharma manufacturers, investors, research organizations, and technology vendors interested in strategic assessment of market potential and competitive position.

Report coverage: Market size and CAGR by offering, application, and end user | Regional analysis across major markets | Competitive landscape and company benchmarking | Technology and innovation assessment | Buyer use cases and market entry barriers | PDF and Excel formats | Customization available by country, region, and segment

Key Companies Profiled

Market Segments Covered in the AI in Genomics Market Report

By Offering Outlook (Revenue, USD Billion, 2021-2034)

Software | Services | Cloud Platforms

By Application Outlook (Revenue, USD Billion, 2021-2034)

Variant Interpretation | Population Genomics | Drug Target Discovery

By End User Outlook (Revenue, USD Billion, 2021-2034)

Research Institutes | Hospitals | Biopharma

By Regional Outlook (Revenue, USD Billion, 2021-2034)

North America (US, Canada) | Europe (Germany, France, UK, Italy, Spain, Netherlands, Russia, Rest of Europe) | Asia Pacific (China, Japan, India, Malaysia, South Korea, Indonesia, Australia, Vietnam, Rest of Asia Pacific) | Latin America (Mexico, Brazil, Argentina, Rest of Latin America) | Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa, Rest of Middle East & Africa)